Tryptophan Metabolites, Cytokines, and Fatty Acid Binding Protein 2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) differ for triggers, mode of start, associated symptoms, evolution, and biochemical traits. Therefore, serious attempts are underway to partition them into subgroups useful for a personalized medicine approach to the disease. Here, we investigated clinical and biochemical traits in 40 ME/CFS patients and 40 sex- and age-matched healthy controls. Particularly, we analyzed serum levels of some cytokines, Fatty Acid Binding Protein 2 (FAPB-2), tryptophan, and some of its metabolites via serotonin and kynurenine. ME/CFS patients were heterogeneous for genetic background, trigger, start mode, symptoms, and evolution. ME/CFS patients had higher levels of IL-17A (p = 0.018), FABP-2 (p = 0.002), and 3-hydroxykynurenine (p = 0.037) and lower levels of kynurenine (p = 0.012) and serotonin (p = 0.045) than controls. Changes in kynurenine and 3-hydroxykynurenine were associated with increased kynurenic acid/kynurenine and 3-hydroxykynurenine/kynurenine ratios, indirect measures of kynurenine aminotransferases and kynurenine 3-monooxygenase enzymatic activities, respectively. No correlation was found among cytokines, FABP-2, and tryptophan metabolites, suggesting that inflammation, anomalies of the intestinal barrier, and changes of tryptophan metabolism may be independently associated with the pathogenesis of the disease. Interestingly, patients with the start of the disease after infection showed lower levels of kynurenine (p = 0.034) than those not starting after an infection. Changes in tryptophan metabolites and increased IL-17A levels in ME/CFS could both be compatible with anomalies in the sphere of energy metabolism. Overall, clinical traits together with serum biomarkers related to inflammation, intestine function, and tryptophan metabolism deserve to be further considered for the development of personalized medicine strategies for ME/CFS.

[1]  A. Komaroff,et al.  Deficient butyrate-producing capacity in the gut microbiome of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients is associated with fatigue symptoms , 2021, medRxiv.

[2]  Ø. Fluge,et al.  A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome , 2021, JCI Insight.

[3]  L. Vécsei,et al.  Monitoring the kynurenine system: Concentrations, ratios or what else? , 2021, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[4]  D. Bogdanos,et al.  Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link? , 2021, Frontiers in Immunology.

[5]  S. Whelan,et al.  Tryptophan, kynurenine pathway, and diabetic ketoacidosis in type 1 diabetes , 2021, PloS one.

[6]  L. Vécsei,et al.  Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway , 2021, Biomedicines.

[7]  E. Fors,et al.  Kynurenine metabolites and ratios differ between Chronic Fatigue Syndrome, Fibromyalgia, and healthy controls , 2021, Psychoneuroendocrinology.

[8]  J. Younger,et al.  ME/CFS: whole genome sequencing uncovers a misclassified case of glycogen storage disease type 13 previously diagnosed as ME/CFS , 2021 .

[9]  A. Oaklander,et al.  Insights from Invasive Cardiopulmonary Exercise Testing of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. , 2021, Chest.

[10]  P. Fisher,et al.  Dysregulated Provision of Oxidisable Substrates to the Mitochondria in ME/CFS Lymphoblasts , 2021, International journal of molecular sciences.

[11]  B. Penninx,et al.  Brain-immune crosstalk in the treatment of major depressive disorder , 2020, European Neuropsychopharmacology.

[12]  E. Puglisi,et al.  Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic Encephalomyelits (CFS/ME) , 2020, Scientific Reports.

[13]  L. Vécsei,et al.  Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway , 2020, International journal of molecular sciences.

[14]  J. Lagopoulos,et al.  Neuroimaging characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review , 2020, Journal of Translational Medicine.

[15]  T. Kleffmann,et al.  A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction , 2020, Journal of translational medicine.

[16]  F. Valtorta,et al.  Prenatal IL-6 levels and activation of the tryptophan to kynurenine pathway are associated with depressive but not anxiety symptoms across the perinatal and the post-partum period in a low-risk sample , 2020, Brain, Behavior, and Immunity.

[17]  J. Ruas,et al.  The Kynurenine connection: how exercise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain. , 2020, American journal of physiology. Cell physiology.

[18]  Eun-su Jang,et al.  Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) , 2020, Journal of Translational Medicine.

[19]  S. Comai,et al.  Tryptophan in health and disease. , 2020, Advances in clinical chemistry.

[20]  M. Hanson,et al.  Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. , 2019, The Journal of clinical investigation.

[21]  M. Ruscica,et al.  Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring , 2019, Cell metabolism.

[22]  T. Dinan,et al.  Focus on the essentials: tryptophan metabolism and the microbiome-gut-brain axis. , 2019, Current opinion in pharmacology.

[23]  D. Staines,et al.  A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID) , 2019, BMC Neurology.

[24]  Eric H. Chang,et al.  Cholinergic Control of Inflammation, Metabolic Dysfunction, and Cognitive Impairment in Obesity-Associated Disorders: Mechanisms and Novel Therapeutic Opportunities , 2019, Front. Neurosci..

[25]  F. Powrie,et al.  Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. , 2019, Immunity.

[26]  M. Martín-Martínez,et al.  Varied Presentation of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and the Needs for Classification and Clinician Education: A Case Series. , 2019, Clinical therapeutics.

[27]  J. Montoya,et al.  Onset Patterns and Course of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2019, Front. Pediatr..

[28]  M. VanElzakker,et al.  Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods , 2019, Front. Neurol..

[29]  F. Valtorta,et al.  Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide , 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[30]  A. Kaczka,et al.  Evaluation of serotonin and dopamine secretion and metabolism in patients with irritable bowel syndrome. , 2018, Polish archives of internal medicine.

[31]  M. Noda,et al.  Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome , 2018, Front. Psychiatry.

[32]  O. Fiehn,et al.  Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics , 2018, Scientific Reports.

[33]  S. Jeon,et al.  Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders , 2018, Current neuropharmacology.

[34]  E. Ben-Chetrit,et al.  Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes , 2018, The New England journal of medicine.

[35]  C. Reardon,et al.  The cholinergic anti‐inflammatory pathway revisited , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[36]  A. Hoeflich,et al.  Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions , 2018, Front. Immunol..

[37]  J. Elson,et al.  Cellular bioenergetics is impaired in patients with chronic fatigue syndrome , 2017, PloS one.

[38]  W. Hong,et al.  Protective Effects of Bifidobacterium on Intestinal Barrier Function in LPS-Induced Enterocyte Barrier Injury of Caco-2 Monolayers and in a Rat NEC Model , 2016, PloS one.

[39]  William A. Walters,et al.  Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome , 2016, Microbiome.

[40]  P. Efthimiou,et al.  Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes , 2016, Modern rheumatology.

[41]  D. Drossman.  Chapter 19: History of Functional Gastrointestinal Symptoms and Disorders and Chronicle of the Rome Foundation , 2016 .

[42]  Mady Hornig,et al.  Distinct plasma immune signatures in ME/CFS are present early in the course of illness , 2015, Science Advances.

[43]  K. Mizuno,et al.  Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study , 2014, The Journal of Nuclear Medicine.

[44]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[45]  W. Khan,et al.  Serotonin and GI Disorders: An Update on Clinical and Experimental Studies , 2012, Clinical and Translational Gastroenterology.

[46]  N. Abumrad,et al.  Enterocyte Fatty Acid Handling Proteins and Chylomicron Formation , 2012 .

[47]  C. Gotti,et al.  Expression of the α7 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS , 2011, Journal of Neuroimmunology.

[48]  P. White.  Chronic fatigue syndrome: Is it one discrete syndrome or many? Implications for the "one vs. many" functional somatic syndromes debate. , 2010, Journal of psychosomatic research.

[49]  Y. Fujii‐Kuriyama,et al.  Hypersensitivity of Aryl Hydrocarbon Receptor-Deficient Mice to Lipopolysaccharide-Induced Septic Shock , 2009, Molecular and Cellular Biology.

[50]  B. V. van Bon,et al.  Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome , 2009, Journal of Medical Genetics.

[51]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[52]  A. Farmer,et al.  Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome , 2005, Journal of psychopharmacology.

[53]  P. Grasby,et al.  Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635 , 2005, Biological Psychiatry.

[54]  H. Onoe,et al.  Reduction of serotonin transporters of patients with chronic fatigue syndrome , 2004, Neuroreport.

[55]  S. Ward,et al.  Chronic fatigue syndrome: new evidence for a central fatigue disorder. , 2003, Clinical science.

[56]  P. Flor-Henry,et al.  Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols , 2003 .

[57]  M. Litaker,et al.  DIABETIC KETOACIDOSIS DEPLETES PLASMA TRYPTOPHAN , 2002, Endocrine research.

[58]  L. Chylack,et al.  3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. , 2000, Biochemistry.

[59]  D. Bell.  The Doctor's Guide To Chronic Fatigue Syndrome: Understanding, Treating,And Living With Cfids , 1994 .